CHAPTER 1 - MARKET SUMMARY
Market Overview
The USA Patient Registry Software Market operates through recurring software subscriptions, implementation fees, data integration, and managed registry services sold to health systems, life sciences sponsors, medical societies, and public agencies. Certified EHR adoption reached 91% of office-based physicians and more than 99% of non-federal acute-care hospitals in 2024, creating a broad digital data foundation for automated enrollment and longitudinal follow-up.
The South and Southeast represented an estimated 31% of 2025 market revenue, supported by large health-system footprints, clinical research activity, and enterprise software operations in North Carolina, Texas, Florida, and Georgia. The United States had 6,100 hospitals and 3,567 system-affiliated community hospitals in 2026, concentrating procurement power and favoring vendors capable of multi-facility deployment, standardized governance, and centralized analytics.
Market Value
USD 820.0 million
2025
Dominant Region
South and Southeast
2025
Dominant Segment
Cloud SaaS
fastest growing, 2025
Total Number of Players
148
Future Outlook
The USA Patient Registry Software Market is projected to increase from USD 820.0 million in 2025 to USD 1,663.0 million by 2031, representing a 12.5% forecast CAGR. The historical market expanded at 12.5% annually during 2020-2025 as providers digitized specialty registries, life sciences sponsors expanded real-world evidence programs, and medical societies modernized quality reporting. Growth remains supported by a broad installed base of certified EHRs and stronger regulatory acceptance of routinely collected clinical data. The forecast assumes sustained procurement of cloud subscriptions, implementation services, API integration, data curation, and registry operations across provider, sponsor, association, and public-sector buyers.
Value growth is expected to outpace deployment growth as buyers purchase higher-value interoperability, automation, analytics, privacy, and managed-service modules. Active paid deployments are forecast to rise from 5.9 thousand in 2025 to 10.3 thousand in 2031, while blended annual revenue per deployment increases from approximately USD 139,000 to USD 161,000. Cloud SaaS is expected to reach 84% of market revenue by 2031, and FHIR/API-enabled deployments should reach 86%. The base projection incorporates procurement friction, cybersecurity expenditure, EHR heterogeneity, and hospital budget pressure, resulting in a conservative terminal estimate below several broader global-market extrapolations.
12.5%
Forecast CAGR
$1,663.0 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2026-2031
Historical CAGR
12.5%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Market sizing and trajectory
Policy and compliance mapping
Buyer demand indicators
Segment structure and levers
Competitive landscape shortlist
CEO-grade risk priorities
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
Market revenue increased from USD 455.0 million in 2020 to USD 820.0 million in 2025. The 2021 trough growth rate of 11.0% reflected delayed provider procurement and implementation constraints, while growth accelerated to a period peak of 13.3% in 2025. The main inflection occurred during 2022-2024 as remote data collection, cloud migration, quality reporting, and life sciences real-world evidence programs moved from pandemic-era workarounds into permanent operating models. Revenue remained concentrated among enterprise platforms and specialist managed-service providers serving complex multi-site registries.
Forecast Market Outlook (2026-2031)
Revenue is forecast to rise from USD 921.0 million in 2026 to USD 1,663.0 million in 2031, with a 12.5% CAGR. Growth remains relatively stable rather than front-loaded, reflecting recurring subscriptions, multi-year implementations, and expanding data services. The terminal year adds USD 187.0 million in annual revenue, the largest absolute increase in the series. Cloud migration, API-based EHR extraction, AI-assisted abstraction, patient-reported outcomes, and post-market evidence mandates should raise platform value per deployment while offsetting slower procurement cycles in hospitals and public agencies.
Locked Market Scope
The market includes software licenses, cloud subscriptions, implementation, interoperability, data management, analytics, support, and managed operations directly attributable to patient registries in the United States. It covers disease, product, health-service, population-health, quality, and research registries. General EHR, clinical-trial management, claims analytics, and broad data platforms are excluded unless revenue is directly linked to registry functionality.
CHAPTER 5 - Market Data
Market Breakdown
The USA Patient Registry Software Market is moving from stand-alone data capture toward cloud-based evidence infrastructure. The table links revenue expansion with deployment volume, cloud mix, and interoperability maturity, the three operating variables most relevant to vendor scale, customer switching costs, and recurring margin quality.
Year | Market Size (USD Mn) | YoY Growth (%) | Active Paid Registry Deployments (000) | Cloud SaaS Revenue Share (%) | FHIR/API-Enabled Deployments (%) | Period |
|---|---|---|---|---|---|---|
| 2020 | $455.0 Mn | +- | 3.7 | 49% | Forecast | |
| 2021 | $505.0 Mn | +11.0% | 4.1 | 53% | Forecast | |
| 2022 | $568.0 Mn | +12.5% | 4.5 | 57% | Forecast | |
| 2023 | $641.0 Mn | +12.9% | 5.0 | 61% | Forecast | |
| 2024 | $724.0 Mn | +12.9% | 5.4 | 65% | Forecast | |
| 2025 | $820.0 Mn | +13.3% | 5.9 | 68% | Forecast | |
| 2026F | $921.0 Mn | +12.3% | 6.5 | 72% | Forecast | |
| 2027F | $1,035.0 Mn | +12.4% | 7.2 | 75% | Forecast | |
| 2028F | $1,164.0 Mn | +12.5% | 7.9 | 78% | Forecast | |
| 2029F | $1,310.0 Mn | +12.5% | 8.6 | 80% | Forecast | |
| 2030F | $1,476.0 Mn | +12.7% | 9.4 | 82% | Forecast | |
| 2031F | $1,663.0 Mn | +12.7% | 10.3 | 84% | Forecast |
Active Paid Registry Deployments
5.9 thousand (2025, United States). Deployment scale determines addressable subscription revenue and services attachment. The United States had 6,100 hospitals in 2026, with 3,567 community hospitals operating inside systems, supporting multi-site contracting and portfolio deployments.
Cloud SaaS Revenue Share
68% (2025, United States). Cloud mix improves release velocity and recurring economics but raises security and data-residency obligations. Predictive AI integrated with EHRs was used by 71% of U.S. hospitals in 2024, strengthening demand for scalable hosted data pipelines.
FHIR/API-Enabled Deployments
63% (2025, United States). Standards-based connectivity lowers manual abstraction and accelerates onboarding. In 2024, 70% of U.S. hospitals enabled patient access through a standards-based API, providing a technical foundation for automated registry enrollment and longitudinal updates.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, buyer preferences, technology adoption, and commercial delivery patterns.
No of Segments
7
Dominant Segment
Solution Type
Fastest Growing Segment
Deployment Model
Solution Type
Deployment Model
End User
Application
Technology
Pricing Model
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, buyer preferences, technology adoption, and distribution patterns.
Solution Type
Disease registries remain the largest revenue pool because oncology, cardiovascular, metabolic, and rare-disease programs require long-duration follow-up, standardized outcomes, and specialist governance. Product registries generate higher implementation intensity where sponsors need safety surveillance and regulatory evidence. Health service and population registries broaden demand toward quality benchmarking and public-health surveillance, supporting diversified vendor portfolios.
Deployment Model
Cloud SaaS is the fastest-growing delivery model because buyers need rapid releases, multi-site access, configurable workflows, and lower local infrastructure burden. Dedicated and private-cloud configurations remain important for sensitive data and enterprise control, while hybrid deployment supports organizations that retain protected health information locally but use cloud analytics, patient engagement, or cross-site evidence services.
CHAPTER 7 - Regional Analysis
Regional Analysis
The United States ranks first among economically comparable patient registry software markets, reflecting its large provider base, life sciences research intensity, mature EHR infrastructure, and regulatory use of real-world evidence. Its 2025 revenue is more than five times the United Kingdom estimate, although Australia, Canada, Germany, and France offer faster percentage growth from smaller bases.
Focus Country Ranking
1st
Focus Country Market Size
USD 820 Mn (2025)
United States CAGR (2026-2031)
12.5%
Focus Country Ranking
1st
Focus Country Market Size
USD 820 Mn (2025)
United States CAGR (2026-2031)
12.5%
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | United States | United Kingdom | Germany | Australia | Canada | France |
|---|---|---|---|---|---|---|
| Market Size (2025) | USD 820 Mn | USD 153 Mn | USD 90 Mn | USD 86 Mn | USD 79 Mn | USD 73 Mn |
| CAGR (%) (2026-2031) | 12.5% | 12.6% | 14.2% | 15.6% | 14.6% | 13.8% |
Market Position
The United States ranks first at USD 820 million in 2025, supported by 91% certified EHR adoption among office-based physicians and the world’s deepest clinical research ecosystem.
Growth Advantage
U.S. CAGR of 12.5% trails Australia at 15.6% and Canada at 14.6%, but its larger installed base produces the highest absolute annual revenue additions among peers.
Competitive Strengths
More than 99% hospital EHR adoption, 70% standards-based patient APIs, and FDA recognition of registry data give U.S. vendors strong data access, product validation, and exportable compliance capabilities.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges and Opportunities
Comprehensive analysis of key factors shaping the USA Patient Registry Software Market, including growth catalysts, operational challenges, and emerging opportunities across healthcare delivery, evidence generation, quality reporting, and patient engagement.
Growth Drivers
Regulatory Acceptance of Real-World Evidence
- FDA explicitly recognizes product and disease registries as real-world data sources, expanding the commercial role of validated longitudinal platforms in safety, effectiveness, and label-support programs. Registry guidance finalized in 2023 (FDA, United States).
- CMS approved 44 unique QCDRs for the 2024 MIPS performance period (CMS, United States), sustaining demand for measure calculation, submission, audit trails, clinician feedback, and specialty benchmarking.
- Product registries are the fastest-growing global solution segment, creating a higher-value profit pool for vendors serving post-market surveillance and long-term outcomes programs. Global market forecast CAGR 13.6% through 2030 (Grand View Research).
Interoperability and Automated Data Capture
- Standards-based API availability reduces custom interface work and enables automated patient access, with 70% of hospitals supporting standards-based patient APIs in 2024 (ONC, United States). Vendors capture value through reusable connectors and faster implementation.
- External exchange maturity supports longitudinal follow-up across care settings: 84% of hospitals often sent and 73% often received outside information in 2023 (ONC, United States). Registry platforms can monetize normalization, identity resolution, and data-quality services.
- FIGmd reports integrations with more than 160 EHR systems and 19 medical societies (company disclosure, United States), demonstrating that connector breadth is a defensible operating asset and a barrier to smaller entrants.
Specialty, Oncology and Rare-Disease Evidence Demand
- The national cancer surveillance infrastructure contains 42.1 million records with 99.1% to 100% population coverage in 2025 submissions (CDC, United States), creating demand for modernization, interoperability, analytics, and rapid reporting.
- CDC supports central cancer registries across 46 states, the District of Columbia, Puerto Rico, Pacific jurisdictions, and the U.S. Virgin Islands (CDC, United States), generating recurring public-sector software and technical-assistance requirements.
- listed more than 594,000 studies across 226 countries in 2026 (NIH, global), allowing U.S. registry vendors to extend disease and product evidence platforms into multinational post-approval and natural-history programs.
Market Challenges
Cybersecurity, Privacy and Consent Exposure
- The Change Healthcare incident affected approximately 192.7 million individuals as reported in 2025 (HHS, United States), increasing buyer scrutiny of subcontractors, access controls, business continuity, and breach indemnification.
- Longitudinal registries retain identifiable data for years, so HIPAA security, consent versioning, de-identification, and state privacy obligations add material implementation and hosting cost. Forecast security and compliance burden embedded in a 17.7% sizing uncertainty range (2025, Ken Research model).
- Cloud scale improves economics but concentrates vendor liability. Buyers increasingly require independent controls, recovery testing, and detailed data-use restrictions, raising entry barriers for firms without enterprise security teams. Cloud SaaS share estimated at 68% in 2025 (United States).
Data Heterogeneity and Integration Cost
- Variation in local coding, workflows, historical data, and specialty documentation requires mapping and validation beyond simple connectivity. More than 160 EHR integrations disclosed by FIGmd (company disclosure, United States) illustrates the operational breadth required.
- Manual abstraction persists where structured fields are incomplete, reducing gross margins and slowing time to value. Health Catalyst reports more than 15% abstraction-cost reduction using ARMUS Hybrid Outcomes (company disclosure, United States), indicating the remaining cost base.
- Data provenance and fitness-for-use validation are required for regulatory evidence, which limits low-cost generic platforms. FDA’s 2024 final guidance (FDA, United States) raises expectations for data relevance, reliability, and documentation.
Concentrated Buyers and Long Procurement Cycles
- Centralized procurement can expand contract value but also lengthen security, legal, integration, and governance reviews. The United States had 397 health systems in 2025 (AHA, United States), concentrating decision authority among fewer buyers.
- Public-health and society registries often depend on grants, member dues, or reporting programs, making renewal timing sensitive to policy and budget cycles. CMS approved 44 QCDRs in 2024 (CMS, United States), a narrower qualified buyer pool than total provider demand.
- Vendors must support implementation before recurring revenue fully scales, increasing working-capital needs. The base model assumes 5.9 thousand paid deployments in 2025 (United States), with enterprise implementations representing a disproportionate share of contract acquisition cost.
Market Opportunities
AI-Assisted Abstraction and Data Quality
- Monetizable modules include NLP extraction, coding suggestions, duplicate detection, query prioritization, and automated quality checks. Veeva reported 90% less site-metric calculation effort in a registry case study (company disclosure, 2023), supporting premium pricing tied to labor savings.
- Hospitals, abstractors, societies, and sponsors benefit through faster submissions and lower labor intensity. Health Catalyst cites more than 15% abstraction-cost reduction (company disclosure, United States), creating a measurable ROI case for automation subscriptions.
- Opportunity realization requires human review, model monitoring, provenance, and bias controls. Vendors that package governance with automation can capture higher recurring revenue as FHIR/API-enabled deployments rise to 86% by 2031 (Ken Research forecast, United States).
Product and Medical Device Post-Market Registries
- Revenue can combine platform subscription, study build, site onboarding, follow-up, analytics, and regulatory reporting. Product registries are identified as the fastest-growing global solution segment through 2030 (Grand View Research), supporting above-market contract values.
- Medical-device and biopharma sponsors benefit from longer patient follow-up and evidence reuse across safety, reimbursement, and clinical strategy. FDA recognized registries within its 2023 registry guidance framework (FDA, United States).
- Scaling requires fit-for-purpose data, governance, and integration with clinical care. Vendors that combine software with evidence design and operations can capture the modeled market’s USD 843 million incremental revenue from 2025 to 2031 (United States).
Managed Registry-as-a-Service
- Monetizable offerings include registry design, data abstraction, help desk, measure operations, analytics, and participant benchmarking. FIGmd reports serving more than 100,000 providers (company disclosure, United States), demonstrating scalable recurring service demand.
- Specialty societies, mid-sized sponsors, and regional health systems gain access to enterprise capabilities without building full internal teams. OpenClinica reports support for 15,000 studies and more than 3 million patients (company disclosure, global).
- Value realization requires standardized implementation playbooks, configurable governance, and reusable connectors. Cloud SaaS revenue share is forecast to reach 84% by 2031 (Ken Research forecast, United States), enabling vendors to combine platform scale with service attachment.
Reconciliation Summary
- Supply-side result of USD 842 million, operational result of USD 808 million, and demand-side result of USD 770 million reconcile to a weighted USD 817 million estimate, rounded to USD 820 million.
- The 2020-2025 historical CAGR of 12.5% reconciles from USD 455 million to USD 820 million.
- The 2025-2031 forecast CAGR of 12.5% reconciles from USD 820 million to USD 1,663 million.
- Deployment volume CAGR is 9.7%, with the balance of value growth driven by cloud mix, analytics, interoperability, security, and managed services.
- Secondary U.S. estimates bracket the base result between USD 776 million and USD 902 million in 2025, while broader global estimates provide an external plausibility boundary.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The market is moderately concentrated at the enterprise tier but fragmented across specialist registry, QCDR, EDC, and managed-service providers. Entry barriers arise from EHR interfaces, evidence governance, security credentials, clinical-domain expertise, and long reference-building cycles.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
IQVIA | - | Durham, North Carolina, United States | 1982 | Patient registries, real-world evidence, registry operations and analytics |
Medidata Solutions | - | New York, New York, United States | 1999 | Cloud registry studies, patient engagement and clinical data capture |
Oracle Life Sciences | - | Austin, Texas, United States | 1977 | Technology-enabled registries, safety, clinical and real-world data services |
Health Catalyst | - | South Jordan, Utah, United States | 2008 | Cancer registries, outcomes registries and AI-assisted abstraction |
Fivos Health | - | West Lebanon, New Hampshire, United States | 2006 | Specialty registries, medical society platforms and analytics |
FIGmd (MRO) | - | Rockford, Illinois, United States | 2010 | QCDR platforms, EHR integration and quality reporting |
ArborMetrix | - | Ann Arbor, Michigan, United States | 2011 | Clinical registries, specialty analytics and provider benchmarking |
Veeva Systems | - | Pleasanton, California, United States | 2007 | Cloud EDC and registry studies for life sciences and medical devices |
OpenClinica | - | Needham, Massachusetts, United States | 2004 | Open and cloud clinical data capture for longitudinal registry studies |
Dacima Software | - | Montreal, Quebec, Canada | 2006 | Configurable patient registries, ePRO and observational research platforms |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Analysis Covered
Market Share Analysis:
Estimates registry-specific revenue concentration across enterprise and specialist provider tiers.
Cross Comparison Matrix:
Compares deployment scale, integrations, growth, and recurring margin performance.
SWOT Analysis:
Assesses product depth, evidence credibility, channel access, and execution risks.
Pricing Strategy Analysis:
Benchmarks subscription, implementation, patient-based, and managed-service monetization models.
Company Profiles:
Reviews ownership, footprint, product focus, partnerships, and strategic positioning.
CHAPTER 10 - REPORT TOC
Market Report Structure
Comprehensive coverage across three strategic phases — Market Assessment, Go-To-Market Strategy, and Survey — delivering end-to-end insights from market analysis and execution roadmap to customer demand validation.
Phase 1Market Assessment Phase
11
Chapters
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Phase 2Go-To-Market Strategy Phase
15
Chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Registry software revenue disclosures reviewed
- Federal interoperability adoption indicators analyzed
- RWE and QCDR rules mapped
- Vendor deployment references systematically benchmarked
Primary Research
- Chief Medical Information Officers interviewed
- Registry Program Directors interviewed
- Real-World Evidence Directors interviewed
- Clinical Data Management Heads interviewed
Validation and Triangulation
- 275 respondent observations cross-validated
- Vendor and buyer estimates reconciled
- Deployment economics independently sanity-checked
- Forecast scenarios pressure-tested with experts
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
No regional reports found.
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
No adjacent reports found.
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals